OncoMatch/Clinical Trials/NCT06741722
Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML
Is NCT06741722 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Decitabine, Azacitidine, Mitoxantrone liposome, Cytarabine, G-CSF for aml.
Treatment: Decitabine, Azacitidine, Mitoxantrone liposome, Cytarabine, G-CSF — The DCMG regimen includes decitabine or azacitidine (hypomethylating agents), mitoxantrone liposome, cytarabine, and granulocyte colony-stimulating factor (G-CSF), comprising four medications. This project initiates a prospective and exploratory clinical study on the DCMG chemotherapy regimen for the treatment of relapsed/refractory AML (Acute Myeloid Leukemia). The study aims to evaluate the efficacy and safety of the DCMG combination chemotherapy regimen in treating relapsed/refractory AML.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: anthracycline (mitoxantrone, mitoxantrone hydrochloride liposome injection)
Previously received mitoxantrone or mitoxantrone hydrochloride liposome injection
Cannot have received: anthracycline (doxorubicin, daunorubicin, idarubicin)
Exception: total cumulative dose of doxorubicin > 360 mg/m² (other anthracycline drugs are converted at a ratio of 1 mg doxorubicin equivalent to 2 mg daunorubicin or 0.5 mg idarubicin)
Previously received doxorubicin or other anthracyclines, with a total cumulative dose of doxorubicin > 360 mg/m² (other anthracycline drugs are converted at a ratio of 1 mg doxorubicin equivalent to 2 mg daunorubicin or 0.5 mg idarubicin)
Cannot have received: major surgery, radiotherapy, chemotherapy, biological therapy, immunotherapy, or experimental treatment
Underwent any major surgery, radiotherapy, chemotherapy, biological therapy, immunotherapy, or experimental treatment within 2 weeks before the first administration of the study drug
Lab requirements
Kidney function
serum creatinine ≤ 1.5 times the upper limit of normal
Liver function
Serum total bilirubin ≤ 1.5 times the upper limit of normal, serum ALT and AST both ≤ 2.5 times the upper limit of the normal range
Cardiac function
Echocardiogram showing left ventricular ejection fraction (LVEF) ≥ 50%
Serum total bilirubin ≤ 1.5 times the upper limit of normal, serum ALT and AST both ≤ 2.5 times the upper limit of the normal range, serum creatinine ≤ 1.5 times the upper limit of normal; Echocardiogram showing left ventricular ejection fraction (LVEF) ≥ 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify